171 related articles for article (PubMed ID: 30185690)
1. Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
Kato TS; Ikeda N; Maurer MS; Ando Y; Tanno K
Circ J; 2019 Feb; 83(3):690. PubMed ID: 30185690
[No Abstract] [Full Text] [Related]
2. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
3. What is this image? 2022 image 1 result: radiologic improvement of transthyretin cardiac amyloidosis after treatment with tafamidis.
Mekritthikrai R; Gomez-Valencia J; Malhotra S
J Nucl Cardiol; 2022 Aug; 29(4):1500-1502. PubMed ID: 35715715
[No Abstract] [Full Text] [Related]
4. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
5. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy.
Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C
Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637
[No Abstract] [Full Text] [Related]
7. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
9. Real-world versus trial patients with transthyretin amyloid cardiomyopathy.
Canepa M; Tini G; Musumeci B; Cappelli F; Milandri A; Mussinelli R; Autore C; Perfetto F; Rapezzi C; Perlini S
Eur J Heart Fail; 2019 Nov; 21(11):1479-1481. PubMed ID: 31339212
[No Abstract] [Full Text] [Related]
10. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
11. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis for the treatment of transthyretin amyloidosis.
Lorenzini M; Elliott PM
Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
[TBL] [Abstract][Full Text] [Related]
13. Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis.
Nishizawa RH; Kawano H; Yoshimuta T; Eguchi C; Kojima S; Minami T; Sato D; Eguchi M; Okano S; Ikeda S; Ueda M; Maemura K
Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):678-686. PubMed ID: 38109497
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
Falk RH
Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
[No Abstract] [Full Text] [Related]
15. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
[TBL] [Abstract][Full Text] [Related]
16. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.
Nawarskas JJ; Shephard EA
Cardiol Rev; 2020; 28(3):156-160. PubMed ID: 32101907
[TBL] [Abstract][Full Text] [Related]
18. Inotersen therapy of transthyretin amyloid cardiomyopathy.
Dasgupta NR; Rissing SM; Smith J; Jung J; Benson MD
Amyloid; 2020 Mar; 27(1):52-58. PubMed ID: 31713445
[No Abstract] [Full Text] [Related]
19. New Drugs Treat Rare Heart Disease Caused by Transthyretin-Mediated Amyloidosis.
Aschenbrenner DS
Am J Nurs; 2019 Sep; 119(9):22-23. PubMed ID: 31449117
[No Abstract] [Full Text] [Related]
20. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
Baldovino S; Costanzo P; Roccatello D
Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
